NEX-I develops ONCOKINE®, a platform that targets cancer cells to induce resistance to existing treatments, enhancing the efficacy of cancer immunotherapy. This approach aims to improve patient outcomes and quality of life by providing a new standard of care in anti-cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to existing treatments, limiting the effectiveness of cancer immunotherapy and leading to poorer patient outcomes. This resistance hinders the ability of the immune system to effectively target and eliminate cancer cells.
Solution
NEX-I is developing ONCOKINE®, a platform designed to target cancer cells and induce resistance to existing treatments. By making cancer cells resistant to current therapies, ONCOKINE® enhances the efficacy of cancer immunotherapy. This approach aims to improve patient outcomes and quality of life by establishing a new standard of care in anti-cancer therapies, allowing the immune system to more effectively combat the disease. The ONCOKINE® platform identifies and validates novel targets that can be leveraged to overcome treatment resistance.
Target Audience
The primary target audience includes cancer patients undergoing immunotherapy, oncologists, and pharmaceutical companies developing novel cancer treatments.
Features
- ONCOKINE® platform identifies validated targets within cancer cells.
- Induces resistance to existing cancer treatments in targeted cells.
- Enhances the effectiveness of cancer immunotherapy.
- Aims to improve patient outcomes and quality of life.